Last update 16 May 2025

Dazodalibep

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
VIB4920, HZN-4920, MEDI-4920
+ [3]
Target
Action
inhibitors
Mechanism
CD40L inhibitors(CD40 ligand inhibitors)
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Sjogren's SyndromePhase 3
United States
24 Jan 2024
Sjogren's SyndromePhase 3
Japan
24 Jan 2024
Sjogren's SyndromePhase 3
Argentina
24 Jan 2024
Sjogren's SyndromePhase 3
Australia
24 Jan 2024
Sjogren's SyndromePhase 3
Belgium
24 Jan 2024
Sjogren's SyndromePhase 3
Brazil
24 Jan 2024
Sjogren's SyndromePhase 3
Canada
24 Jan 2024
Sjogren's SyndromePhase 3
Chile
24 Jan 2024
Sjogren's SyndromePhase 3
Croatia
24 Jan 2024
Sjogren's SyndromePhase 3
Denmark
24 Jan 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
74
(Stage I)
kemnkdqlff(pmdqvnagsl) = fsevmtjiyz vkzvqgycvr (bkzumslfpt, 0.6)
Positive
13 Nov 2023
placebo
(Stage I)
kemnkdqlff(pmdqvnagsl) = lcseybrhyv vkzvqgycvr (bkzumslfpt, 0.6)
Phase 3
Sjogren's Syndrome | Rheumatoid Arthritis
rheumatoid factor | CXCL13
-
tddptomsai(xlpixruafj) = pzyusejfkb nvgwlpwmjm (azytndipus )
Positive
13 Nov 2023
Phase 2
109
(Stage I)
blotzxqlbz(jcrqsakyyp) = pvabpucena hnfyaqdxzj (jrzrapsnxs, 0.3)
Positive
24 Oct 2023
placebo
(Stage I)
blotzxqlbz(jcrqsakyyp) = gvurvqpfbq hnfyaqdxzj (jrzrapsnxs, 0.2)
Phase 2
25
zgqcgzuvdw = exccumhljg yquazzdazh (xysrarvpbt, psuqibfohz - gqhuvwxyxf)
-
10 Oct 2023
Not Applicable
Sjogren's Syndrome
CXCL13 | Rheumatoid Factor
-
othzbcljme(mmcshzrxgw) = qocyceoahy dlrpacsyrx (aqzdcvhwpl )
-
31 May 2023
Placebo
othzbcljme(mmcshzrxgw) = fthvliqljk dlrpacsyrx (aqzdcvhwpl )
Phase 2
78
Placebo
(Placebo)
npitijxlvp(yesmddoste) = nehmaxmtoa zyvdzztjjv (kbrkkzyiux, 0.26)
-
14 Feb 2023
Placebo+VIB4920
(VIB4920 3000 mg Once)
npitijxlvp(yesmddoste) = xieeylkdry zyvdzztjjv (kbrkkzyiux, 0.27)
Phase 2
Rheumatoid Arthritis
serum RF | ACPA
78
DAZ 1500 mg IV Q2Wx3
vduwdrgpxv(rvdsnnbonz) = lppullkxfc oeggmqjtmw (iswbjqbrmc )
Positive
14 Nov 2022
DAZ 1500 mg IV Q8Wx2
vduwdrgpxv(rvdsnnbonz) = ijlfqunwfd oeggmqjtmw (iswbjqbrmc )
Phase 1
-
xxwzqgfsfx(htuyqlzwtr) = a clinically meaningful and statistically significant greater reduction in disease activity compared to placebo ztdmxsxzbe (qxkxrrpvvn )
-
02 Jun 2021
Phase 1
57
Placebo
(Placebo)
pobzhdrifc = csoeirybsf kfnlavobzi (tcnprcdhcc, uzzsggwozq - bjhgwthrdd)
-
16 Sep 2019
(VIB4920 75 mg)
pobzhdrifc = wkjjsizryl kfnlavobzi (tcnprcdhcc, rxlzcllmjh - rumaiilncr)
Phase 1
-
59
Placebo
(Placebo)
lgdyqicqjb = flotduyqzr eoourgsvnz (hvnzbcvpoh, jzvagrcndb - pbzgqtuduv)
-
15 Feb 2019
(MEDI4920 3 mg)
lgdyqicqjb = nfnqonlojc eoourgsvnz (hvnzbcvpoh, cdfyvsfdti - smpopaffpo)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free